

## SHARESOC COMPANY SEMINAR

### STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

*(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).*

**Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.**

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

#### **ShareSoc Investment Warning - Company Presentations**

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.



# N4P – N4 Pharma

0.58p ↑ 0.00 0%



EMS: 150k

Healthcare · Highly Speculative · Micro Cap · Sucker Stock

Market Cap  
Enterprise Value  
Revenue  
Position in Market

£2.27m  
£1.09m  
£5.86k  
1393rd / 1,527

Quality  
Value  
Momentum

StockRank™

9  
2  
36  
6



### Momentum

Relative Strength (%)	
1m	-15.8%
3m	-14.7%
6m	-2.78%
1y	-29.1%
Volume Change (%)	
10d / 3m	+18.2%
Price vs... (%)	
52w High	-39.5%
50d MA	-4.15%
200d MA	-0.637%

### Growth & Value

Trailing 12m		Industry	Market
PE Ratio (ttm)	n/a		
PEG Ratio (ttm)	n/a		
EPS Growth (ttm)	n/a		
Dividend Yield (ttm)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	1.82		
Price to Tang. Book	1.91		
Price to Free Cashflow	n/a		
Price to Sales	387.37		
EV to EBITDA	n/a		

### Shareholder Activity

	Buy / Hold / Sell
Institutions	Insufficient data available
Directors	
Community	Insufficient data available

Screens Passed: 0 Long 1 Short

N4P qualifies for **Altman Z-Score Screen** (Short Selling)  
[View Screen](#) [View Checklists](#)


### Quality

	Industry	Market
Return on Capital	-99.3%	
Return on Equity	-83.3%	
Operating Margin	-21,667.75%	

### Financial Summary

Fiscal Year End	2018	2019	2020	2021	2022	2023	TTM	2024E	2025E	CAGR / Avg
<b>Total Revenue</b>	£m	0.073	0.000	0.000	0.000	0.000	0.002	0.006		-51.5%
<b>Operating Profit</b>	£m	-1.42	-0.947	-1.56	-1.84	-1.19	-1.42	-1.27		
<b>Net Profit</b>	£m	-1.18	-0.876	-1.30	-1.54	-1.03	-1.28	-1.12		
<b>EPS Reported</b>	p	-1.32	-0.875	-0.957	-0.853	-0.552	-0.526	-0.422		
<b>EPS Normalised</b>	p	-1.32	-0.875	-0.957	-0.853	-0.552	-0.526	-0.422		
<b>EPS Growth</b>	%									
<b>PE Ratio</b>	x									
<b>PEG</b>										
<b>Profitability</b>										
<b>Operating Margin</b>	%	-1,946					-73,056	-21,668		-12,500%
<b>ROA</b>	%		-82.1	-53.4	-50.1	-45.7		-86.0		
<b>ROCE</b>	%	-161	-96.0	-42.8	-86.5	-57.1	-119	-99.3		-93.8%
<b>ROE</b>	%		-93.9	-56.2	-53.4	-48.8	-79.4	-83.3		-66.3%
<b>Cashflow</b>										
<b>Op. Cashflow ps</b>	p	-1.50	-0.803	-1.01	-0.979	-0.444	-0.496	-0.373		
<b>Capex ps</b>	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000		
<b>Free Cashflow ps</b>	p	-1.50	-0.803	-1.01	-0.979	-0.444	-0.496	-0.373		
<b>Dividends</b> <span>Ex: 19 May '97 / Pay: 1 Jul '97</span>										
<b>Dividend ps</b>	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000		
<b>Dividend Growth</b>	%									
<b>Dividend Yield</b>	%						0.000	0.000	0.000	
<b>Dividend Cover</b>	x									
<b>Balance Sheet</b>										
<b>Cash etc</b>	£m	0.793	0.966	3.56	1.78	1.92	1.03	1.20		5.31%
<b>Working Capital</b>	£m	0.880	0.987	3.66	2.13	2.09	1.13	1.22		5.17%

### Health Trend (F-Score)



### Bankruptcy Risk (Z2-Score)



### Earnings Manipulation Risk (M-Score)

n/a

### Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	0.0	0.0	0.0
Net Gearing %	-96.40	-101.36	-96.4
Cash / Assets %	90.25		90.2
<b>Liquidity (ttm)</b>			
Curr. Ratio			22.73
Quick Ratio			22.73
Interest Cov.			-3,023.17
<b>Efficiency (ttm)</b>			
Asset Turnover			0.00
Recs Turnover			0.17
Stock Turnover			n/a


Fiscal Year End Dec		2018	2019	2020	2021	2022	2023	TTM	2024E	2025E	CAGR / Avg
Net Debt	£m	-0.793	-0.966	-3.56	-1.78	-1.92	-1.03	-1.20			
Net Fixed Assets	£m	0.000	0.000	0.000	0.000	0.000	0.000	0.000			
Book Value	£m	0.880	0.987	3.66	2.13	2.09	1.13	1.25			5.09%
Average Shares	m	89	100	136	181	186	243	260			22%
Book Value ps	p	0.967	0.973	2.02	1.18	0.893	0.420	0.317			-15.4%

**FINANCIAL BRIEF:** For the six months ended 30 June 2024, N4 Pharma PLC revenues increased from £0K to £4K. Net loss... [See more](#)

**Recent History**

Latest interim period vs. prior period	Industry	Market
Sales Growth	n/a	
EPS Growth	n/a	
3yr Compound Annual Growth Rate	Industry	Market
Sales CAGR	n/a	
EPS CAGR	n/a	
DPS CAGR	n/a	

**Graphical History**




**Analyst Forecasts**

Price Target: (0.00% below Price)	31st Dec 2024			31st Dec 2025		
Est. Long Term Growth Rate:	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Consensus Estimate						
1m Change						
3m Change						

**Analyst Consensus**

0 brokers



EPS

**Profile Summary**

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellula... [Read more](#)

**Directors**

- Luke Cairns EDR (43)
- Nigel Theobald CEO
- Christopher Britten NEC
- Michael Palfreyman NID (78)

**Last Annual:** Dec 31, 2023  
**Last Interim:** Jun 30, 2024  
**Incorporated:** Jul 6, 1979  
**Public Since:** Jun 7, 2005  
**Ex Date:** May 19, 1997  
**Payment Date:** Jul 1, 1997  
**No. of Employees:** 5  
**No. of Shareholders:** n/a


**Sector:** Healthcare  
**Industry:** Biotechnology & Medical Research  
**Index:** FTSE AIM All Share Index, AIM Health Care Index  
**Exchange:** LSE AIM Market  
**Asset Category:** Common Stock  
**Shares in Issue:** 394,780,349  
**Free Float:** 323,819,228 (82.03%)  
**Eligible for:**

**Healthcare**  
**Biotechnology & Medical Research**  
**FTSE AIM All Share Index, AIM Health Care Index**  
**LSE AIM Market**  
**Common Stock**  
**394,780,349**  
**323,819,228 (82.03%)**

**Address:** [Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom](#)  
**Web:** <https://www.n4pharma.com/>  
**Phone:** +441332690061  
**Auditors:** Saffery Champness LLP

**N4P Share Price Performance**

Share Price	Volume	Bid - Ask	Low - High	Spread
0.58p	25,190	0.55p - 0.60p	0.00p - 0.00p	870bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
↓ 0.00 0%	2,108,784	0.58p - 0.58p	0.37p - 0.95p	-0.554



**Latest News for N4P**

Tue, Feb 18, 2025 Announcement

**N4 Pharma PLC - Holding(s) in Company**

Feb 7, 2025 Announcement

**RCS - N4 Pharma PLC - Investor Webinar**

Jan 27, 2025 Announcement

**RCS - N4 Pharma PLC - Investor Webinar**

Jan 16, 2025 Announcement

**RCS - N4 Pharma PLC - N4 Pharma Non-Executive Director Q&A**

Jan 8, 2025 Announcement

**N4 Pharma PLC - Directorate Changes**

**Similar to N4P**

Compare

<input type="checkbox"/>	Avenue Therapeutics <b>Sucker Stock</b>	9
<input type="checkbox"/>	Matinas BioPharma Holdings <b>Value Trap</b>	8
<input type="checkbox"/>	Respiratorius AB (publ) <b>Sucker Stock</b>	13
<input type="checkbox"/>	Revive Therapeutics <b>Sucker Stock</b>	15
<input type="checkbox"/>	ValiRx <b>Sucker Stock</b>	5
<input type="checkbox"/>	Vaccinex <b>Sucker Stock</b>	10
<input type="checkbox"/>	Vincerx Pharma <b>Value Trap</b>	7
<input type="checkbox"/>	Zyversa Therapeutics <b>Value Trap</b>	7

**Upcoming Events for N4P**

Monday, April 21st 2025  
**Full Year 2024 N4 Pharma PLC Earnings Release**

Friday, May 23rd 2025  
**N4 Pharma PLC Annual Shareholders Meeting**

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2025

© Stockopedia 2025, Refinitiv, Share Data Services.

- **Important Information:** To use Stockopedia, you must accept our Terms of Use, Privacy and Disclaimer & FSG. All financial services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.
- This communication cannot substitute for professional investment advice or independent factual verification. Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.
- Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. Stockopedia looks for stocks that meet certain pre-defined criteria and presents the results to help users perform their own research. For more Important Information please refer to the Disclaimer section in the Stockopedia website.
- This communication may contain general Financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
- Company data is derived from data provided by Refinitiv
- Each company on Stockopedia is evaluated on the basis of hundreds of fundamental and technical metrics that measure a company's Quality, Value, Growth, and Momentum.
- QVM StockRanks™:
  - This measure equally blends the Quality, Value and Momentum ranks into a core metric, the StockRank.
- QualityRank™:
  - The QualityRank is based on a composite of carefully selected company factors based on the latest academic research into understanding 'Quality'. The factors used are inspired by the writings of Warren Buffett, Joseph Piotroski, Edward Altman and Messod Beneish, as well as recent papers from Robert Novy-Marx of the University of Chicago and National Bureau of Economic Research.
  - Each company in the market is ranked from 1 to 100 for each of these Quality Factors and a composite score is calculated as a weighted average of all these values. The QualityRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- ValueRank™:

- Our ValueRank is based on a composite of the following Value factors: Price to Book Value ; Price to Earnings ; Price to Free Cash Flow ; Dividend Yield % ; Price to Sales ; Earnings Yield %
- Consistent with the value investing philosophy, we use historic ratios for each of these metrics, rather than factoring in analyst forecasts. Each company in the market is ranked from 1 to 100 for each of these value ratios and a composite score is calculated as the weighted average of all valid values. The ValueRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- MomentumRank™:
  - The MomentumRank is based on a composite of the following Price and Estimate Momentum Factors.
  - Price Momentum Factors:
    - Proximity of current share price to the 52 week high ; 50 day vs 200 day moving averages ; 1 year Relative Strength of the share price vs the market ; 6 Month Relative Strength of the share price vs the market.
  - Earnings Momentum Factors:
    - EPS estimate upgrades within the last one month for next financial year ; EPS estimate upgrades within the last three months for this financial year ; EPS surprise percentage based on the latest reported financials ; Scaled earnings surprise based on the standard deviation of the original Consensus forecast ; Consensus broker recommendation upgrade over the last month
  - Each company in the market is ranked from 1 to 100 for each of these momentum ratios and a composite score is calculated as a weighted average of all valid values. The MomentumRank is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
  - When a company has no broker coverage we cannot calculate earnings momentum. As a result the Momentum Rank is calculated using price momentum factors alone.

**SEEN – SEEN**  
 Stapleton Capital  
**4.00p** ↓ -0.60 -13.04%  
 EMS: 20k

Market Cap £5.62m  
 Enterprise Value £4.71m  
 Revenue £1.60m  
 Position in Market 1285th / 1,527

Quality 18  
 Value 9  
 Momentum 81  
 StockRank™ 25

Technology · Highly Speculative · Micro Cap · Momentum Trap



**Momentum**

Relative Strength (%)	
1m	+10.9% ●
3m	+10.9% ●
6m	+62.6% ●
1y	-15.6% ●
Volume Change (%)	
10d / 3m	+281% ●
Price vs... (%)	
52w High	-16.4% ●
50d MA	+20.1% ●
200d MA	+34.7% ●

**Growth & Value**

12m Forecast Rolling		Industry	Market
PE Ratio (f)	n/a		
PEG Ratio (f)	n/a		
EPS Growth (f)	n/a		
Dividend Yield (f)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	2.45		
Price to Tang. Book	11.00		
Price to Free Cashflow	n/a		
Price to Sales	3.52		
EV to EBITDA	n/a		

**Shareholder Activity**

Buy / Hold / Sell	
Institutions	
Directors	
Community	Insufficient data available

Screens Passed: 0 Long 1 Short

SEEN qualifies for **Altman Z-Score Screen** (Short Selling)  
[View Screen](#) [View Checklists](#)

**Quality**

	Industry	Market
Return on Capital	-161.9%	
Return on Equity	-96.9%	
Operating Margin	-234.38%	

**Financial Summary**

Fiscal Year End Dec	2018	2019	2020	2021	2022	2023	TTM	2024E	2025E	CAGR / Avg	
Total Revenue	\$m	0.000	0.000	10.1	8.54	3.25	2.05	2.02	4.06	6.27	
Operating Profit	\$m	-0.114	-0.499	-3.95	-3.51	-10.7	-5.28	-4.74			
Net Profit	\$m	-0.111	-0.491	-3.62	-3.19	-10.3	-5.14	-4.70	-0.890	-0.605	
EPS Reported	¢	-3.64	-16.1	-7.25	-6.39	-20.5	-5.51	-5.01			
EPS Normalised	¢	-3.64	-16.1	-7.25	-6.39	-10.5	-4.05	-3.56	-1.41	-0.504	
EPS Growth	%										
PE Ratio	x										
PEG											
Profitability											
Operating Margin	%			-39.0	-41.2	-329	-257	-234			-111%
ROA	%		-3.54	-15.0	-15.9	-73.3		-110			
ROCE	%	-6.29	-2.13	-20.0	-21.2	-127	-161	-162			-56.4%
ROE	%		-4.09	-17.6	-18.3	-84.5	-89.3	-96.9			-42.8%
Cashflow											
Op. Cashflow ps	¢	-1.96	-17.0	-4.62	-3.35	-0.840	-1.54	-1.05			
Capex ps	¢	0.000	0.000	3.86	3.08	1.46	0.910	0.670			
Free Cashflow ps	¢	-1.96	-17.0	-8.48	-6.43	-2.30	-2.45	-1.72			
Dividends											
Dividend ps	¢	0.000	0.000	0.000	0.000	0.000	0.000	0.000			
Dividend Growth	%										
Dividend Yield	%						0.000	0.000	0.000		
Dividend Cover	x										
Balance Sheet											
Cash etc	\$m	1.87	9.76	5.34	2.09	1.24	1.06	1.15			-10.7%
Working Capital	\$m	1.81	9.14	4.72	1.58	2.40	0.908	0.663			-12.9%

**Health Trend (F-Score)**



**Bankruptcy Risk (Z2-Score)**



**Earnings Manipulation Risk (M-Score)**

n/a

**Other Ratios**

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	0.0	0.0	0.0
Net Gearing %	-39.61	-177.89	-39.6
Cash / Assets %	27.71		27.7
Liquidity (ttm)			
Curr. Ratio			1.54 ●
Quick Ratio			1.54 ●
Interest Cov.			100.00 ●
Efficiency (ttm)			
Asset Turnover			0.47
Recs Turnover			2.39
Stock Turnover			n/a


Fiscal Year End Dec		2018	2019	2020	2021	2022	2023	TTM	2024E	2025E	CAGR / Avg
Net Debt	\$m	-1.87	-9.76	-5.14	-2.09	-1.24	-1.06	-1.15			
Net Fixed Assets	\$m	0.000	0.002	0.002	0.002	0.002	0.002	0.002			
Book Value	\$m	1.81	22.2	18.9	16.0	8.27	3.25	2.91			12.4%
Average Shares	m	3	3	50	50	50	93	94			98%
Book Value ps	¢	59.6	44.5	37.9	32.1	8.85	3.48	3.12			-43.3%

**FINANCIAL BRIEF:** For the six months ended 30 June 2024, SEEEN PLC revenues decreased 3% to \$1.1M. Net loss decreased 31% to... [See more](#)

**Recent History**

	Latest interim period vs. prior period	Industry	Market
Sales Growth	-2.67%	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>
EPS Growth	n/a	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>
3yr Compound Annual Growth Rate		Industry	Market
Sales CAGR	-41.29%	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>
EPS CAGR	n/a	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>
DPS CAGR	n/a	<div style="width: 100%;"></div>	<div style="width: 100%;"></div>


**Graphical History**




**Analyst Forecasts**

Price Target: <b>£0.20</b> (332.55% above Price)	31st Dec 2024			31st Dec 2025		
	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Est. Long Term Growth Rate:						
Consensus Estimate	-702.72k	-1.1	0.0	-477.54k	-0.4	0.0
1m Change				+12.72k	+0.0	
3m Change				-840.00	0.0	

**Analyst Consensus**



**EPS 2024 / 2025**



**Profile Summary**

SEEEN Plc is a United Kingdom-based company that operates a global media and technology platform. The platform delivers key video moments and video commerce. The Company leverage its artificial intelligence (AI) and machine learning technology to more momentize video and to license such capabilit... [Read more](#)

**Directors**

- Patrick Desouza NEC (61)
- Adrian Hargrave CEO
- David Anton NID
- Mark Williams NID
- Michael Zigman NID

Last Annual	Dec 31, 2023
Last Interim	Jun 30, 2024
Incorporated	Feb 15, 2017
Public Since	Sep 21, 2017
Ex Date	
Payment Date	
No. of Employees	14
No. of Shareholders	n/a


Sector	
Industry	
Index	
Exchange	
Asset Category	
Shares in Issue	
Free Float	
Eligible for	

Technology  
 Software & IT Services  
 FTSE AIM All Share Index, AIM Technology Index  
 LSE AIM Market  
 Common Stock  
 122,241,641  
 68,866,034 (56.34%)  
 ✓ ISAs ✓ SIPPs

**Address** [27-28 Eastcastle Street, LONDON, W1W 8DH, United Kingdom](#)  
<https://seen.com/>  
**Web**  
**Phone**  
**Auditors** Crowe U.K. LLP

SEEN Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread
4.00p	43,165	3.50p - 4.50p	0.00p - 0.00p	2,500bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
↓ -0.60 -13.04%	69,174	4.00p - 4.00p	2.40p - 5.50p	1.701



Latest News for SEEN

- Tue, Feb 18, 2025 News

**Brief: Seen Expects 2024 Adjusted EBITDA Loss To Reduce By 33% To \$0.4 Million**
- Tue, Feb 18, 2025 Announcement

**SEEN PLC - Trading Update, Contract Win and Presentation**
- Jan 31, 2025 Announcement

**SEEN PLC - Total Voting Rights**
- Jan 31, 2025 Announcement

**AIM - AIM Notice - 31/01/2025**
- Jan 29, 2025 Announcement

**SEEN PLC - Subscription for new ordinary shares**

Upcoming Events for SEEN

- Tuesday, February 25th 2025

**Seen PLC Investor Presentation**
- Thursday, July 3rd 2025

**Full Year 2024 Seen PLC Earnings Release**

Similar to SEEN

Compare

- Asset Entities**  
*Sucker Stock* 2
- Conferize A/S**  
*Sucker Stock* 0
- Digitalbox**  
*High Flyer* 57
- Grom Social Enterprises**  
*Value Trap* 33
- Love Global**  
*Neutral* 79
- Live World**  
*Neutral* 72
- Personas Social**  
*Neutral* 43
- Tinybeans**  
*Sucker Stock* 23

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2025

© Stockopedia 2025, Refinitiv, Share Data Services.

- Important Information:** To use Stockopedia, you must accept our Terms of Use, Privacy and Disclaimer & FSG. All financial services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.
- This communication cannot substitute for professional investment advice or independent factual verification. Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.
- Information in this commentary is current as at date prepared unless otherwise stated. However, please bear in mind that investments can go up or down in value, and that past performance is not a reliable indicator of future performance. Stockopedia looks for stocks that meet certain pre-defined criteria and presents the results to help users perform their own research. For more Important Information please refer to the Disclaimer section in the Stockopedia website.
- This communication may contain general Financial product advice. It has been prepared without taking into account your personal circumstances, and you should therefore consider its appropriateness in light of your objectives, financial circumstances and needs before acting on it.
- Company data is derived from data provided by Refinitiv
- Each company on Stockopedia is evaluated on the basis of hundreds of fundamental and technical metrics that measure a company's Quality, Value, Growth, and Momentum.
- QVM StockRanks™:

  - This measure equally blends the Quality, Value and Momentum ranks into a core metric, the StockRank.
- QualityRank™:

  - The QualityRank is based on a composite of carefully selected company factors based on the latest academic research into understanding 'Quality'. The factors used are inspired by the writings of Warren Buffett, Joseph Piotroski, Edward Altman and Messod Beneish, as well as recent papers from Robert Novy-Marx of the University of Chicago and National Bureau of Economic Research.
  - Each company in the market is ranked from 1 to 100 for each of these Quality Factors and a composite score is calculated as a weighted average of all these values. The QualityRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- ValueRank™:

- Our ValueRank is based on a composite of the following Value factors: Price to Book Value ; Price to Earnings ; Price to Free Cash Flow ; Dividend Yield % ; Price to Sales ; Earnings Yield %
- Consistent with the value investing philosophy, we use historic ratios for each of these metrics, rather than factoring in analyst forecasts. Each company in the market is ranked from 1 to 100 for each of these value ratios and a composite score is calculated as the weighted average of all valid values. The ValueRank™ is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
- MomentumRank™:
  - The MomentumRank is based on a composite of the following Price and Estimate Momentum Factors.
  - Price Momentum Factors:
    - Proximity of current share price to the 52 week high ; 50 day vs 200 day moving averages ; 1 year Relative Strength of the share price vs the market ; 6 Month Relative Strength of the share price vs the market.
  - Earnings Momentum Factors:
    - EPS estimate upgrades within the last one month for next financial year ; EPS estimate upgrades within the last three months for this financial year ; EPS surprise percentage based on the latest reported financials ; Scaled earnings surprise based on the standard deviation of the original Consensus forecast ; Consensus broker recommendation upgrade over the last month
  - Each company in the market is ranked from 1 to 100 for each of these momentum ratios and a composite score is calculated as a weighted average of all valid values. The MomentumRank is then calculated between zero and 100 for this composite score, where 100 is best and zero is worst.
  - When a company has no broker coverage we cannot calculate earnings momentum. As a result the Momentum Rank is calculated using price momentum factors alone.